Clinical trials: COVID19 ARDS
COVID-19, Acute Respiratory Distress Syndrome
Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery
An informational evaluation of COVID-19 patients who receive low-level laser therapy in addition to a normal regimen of treatment for symptoms associate with COVID-19.
- Trial name
- NCT05258617
- Testing
- LLLT Photobiomodulation
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ward Photonics LLC
Covid-19
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
- Trial name
- NCT04522817
- Testing
- CLBS119
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Covid19-associated ARDS, Covid19
A First-in-Human Study of AV-001 in Healthy Subjects
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects.
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Trial name
- NCT04737486
- Testing
- AV-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vasomune Therapeutics, Inc.
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
COVID-19, ARDS
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…
- Conditions
- COVID-19, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04452097
- Testing
- Human umbilical cord mesenchymal stem cells + best supportive care
- Sponsor
- Baylx Inc.
Covid19, COVID-19 Pneumonia
imPulse™ Una Infrasound-to-ultrasound E-stethoscope
This study generates robust, uniform clinical data across emerging COVID-19 strains to train ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for digital diagnostic feature synthesis of…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT04941209
- Testing
- imPulse™ Una infrasound-to-ultrasound e-stethoscope, (PPA >95%) FDA EUA RT-PCR, HR-CT-scan
- Where
- 3 sites in Democratic Republic of the Congo, India and 1 more
- Volunteers
- 702 people
- Sponsor
- Level 42 AI, Inc.
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
COVID-19 Pneumonia, COVID-19 Respiratory Infection
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05212532
- Testing
- EOM613
- Where
- 4 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- EOM Pharmaceuticals
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Trial name
- GARDEN (NCT04659109)
- Testing
- glenzocimab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Acticor Biotech
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
COVID-19 Pneumonia, Acute Respiratory Distress Syndrome
Respiratory COVID-19: A Randomized, Sham-Controlled Study
A study of intubated critically ill patients infected with SARS-COV-2 to evaluate the safety and treatment effects of ultraviolet-A (UVA) light administered by a novel device via endotracheal tube in a first-in-human study.
- Conditions
- COVID-19 Pneumonia, Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Respiratory Infection
- Trial name
- NCT05166915
- Testing
- UVA Light Emitting Catheter
- Where
- 2 sites in Spain
- Sponsor
- Aytu BioPharma, Inc.
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
ARDS
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe…
- Trial name
- MACoVIA (NCT04367077)
- Testing
- MultiStem
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Healios K.K.
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
COVID-19, ARDS
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients…
- Trial name
- EXIT-COVID19 (NCT04493242)
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Direct Biologics, LLC
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of AMY-101, a potent C3 inhibitor, for the management of patients with ARDS caused by SARS-CoV-2…
- Trial name
- SAVE (NCT04395456)
- Testing
- AMY-101, WFI 5% glucose
- Volunteers
- 144 people
- Sponsor
- Amyndas Pharmaceuticals S.A.